SCHEMBL794593

SCHEMBL794593

CN(Cc1cccc2ccccc12)C(=O)CCSC(=O)N1CCCC2CCCCC21

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.47
METAP2 P50579 7/20 0.44
METAP1 P53582 3/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
UTS2R Q9UKP6 1/20 0.40
TACR1 P25103 1/20 0.39
PREP P48147 1/20 0.38
DPP4 P27487 2/20 0.38
MAPK1 P28482 1/20 0.38
KDM4E B2RXH2 1/20 0.37
APOBEC3A P31941 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771335 0.85 SIGMAR1 (0.48) SIGMAR1METAP2METAP1MEN1KMT2A
SCHEMBL770128 0.85 SIGMAR1 (0.48) SIGMAR1METAP2METAP1MEN1KMT2A
SCHEMBL771188 0.84 NPC1 (0.48) SIGMAR1MEN1KMT2AMAPK1NPC1
SCHEMBL771325 0.83 SIGMAR1 (0.47) SIGMAR1METAP2METAP1MEN1KMT2A
SCHEMBL771404 0.81 SIGMAR1 (0.46) SIGMAR1METAP2METAP1MEN1KMT2A
SCHEMBL770856 0.78 NPC1 (0.35) DPP4NPC1RAB9ASMN1; SMN2
SCHEMBL771674 0.76 NPC1 (0.34) SIGMAR1NPC1RAB9ASMN1; SMN2
SCHEMBL7265331 0.75 KMT2A (0.46) SIGMAR1METAP2METAP1MEN1KMT2A
SCHEMBL794594 0.74 SIGMAR1 (0.36) SIGMAR1MEN1KMT2AKDM4ENPC1
SCHEMBL7293796 0.74 KMT2A (0.45) SIGMAR1METAP2METAP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SIGMAR1 3447/4885METAP2 3787/4885METAP1 1041/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SIGMAR1 3410/4885METAP2 3805/4885METAP1 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.